苏州泽璟生物制药股份有限公司

Chinese biopharmaceutical company headquartered in Kunshan, Suzhou, Jiangsu and listed on the Shanghai STAR Market under code 688266, the first company admitted there under the unprofitable-issuer standard. Develops and commercialises innovative small molecule and biologic medicines for oncology, haemostasis and liver disease, with jaktinib for myelofibrosis and alopecia areata, recombinant human thrombin and a pipeline of multispecific antibodies and targeted therapies, supported by its own research, clinical development and manufacturing.